Department of Molecular and Cellular Sports Medicine, Institute of Cardiovascular Research and Sports Medicine, German Sport University Cologne, Cologne, Germany.
Department I of Internal Medicine, Center for Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.
Support Care Cancer. 2021 Aug;29(8):4859-4866. doi: 10.1007/s00520-021-06035-w. Epub 2021 Feb 5.
Physical activity promises to reduce disease-related symptoms and therapy-related side effects in patients suffering from aggressive lymphoma (L) or acute leukemia (AL). For an efficient training program, determination of patients' physical capacity with a purposive exercise test is crucial. Here, we evaluated the feasibility and suitability of a graded exercise test (GXT) frequently applied in patients suffering from solid tumors by assessing whether patients achieved criteria for maximal exercise testing according to the American College of Sports Medicine (ACSM).
The GXT was performed by 51 patients with an aggressive L or AL prior to the start or in the earliest possible phase of high-dose chemotherapy, following a recommended protocol for cancer patients, starting at 20 Watts (W), with an increase of 10 W/min until volitional exhaustion. Subsequently, we investigated whether the following ACSM criteria were fulfilled: (1) failure of heart rate to increase despite increasing workload, (2) post-exercise capillary lactate concentration ≥ 8.0 mmol L, (3) rating of perceived exertion at exercise cessation > 17 on the 6-20 Borg Scale.
Out of 51 patients, two, six, and 35 participants met the first, second, and third criterion, respectively. No relevant relationships between the completion of the criteria and patients' characteristics (e.g., gender, age) were found.
Although results of this study suggest a general feasibility of the applied GXT, the ACSM criteria were not met by the majority of the participants. Therefore, this study raises doubts about the suitability of the GXT protocol and the ACSM criteria for this group of patients.
身体活动有望减轻患有侵袭性淋巴瘤(L)或急性白血病(AL)患者的疾病相关症状和治疗相关副作用。对于有效的训练计划,通过有针对性的运动测试确定患者的身体能力至关重要。在这里,我们通过评估患者是否根据美国运动医学学院(ACSM)的标准达到最大运动测试的标准,评估了常用于实体瘤患者的递增运动测试(GXT)的可行性和适用性。
在开始进行高强度化疗之前或尽可能早的阶段,51 例患有侵袭性 L 或 AL 的患者进行了 GXT,遵循适用于癌症患者的推荐方案,从 20 瓦(W)开始,每 10 瓦/分钟增加一次,直到自愿力竭。随后,我们研究了以下 ACSM 标准是否得到满足:(1)尽管工作量增加,但心率仍未增加,(2)运动后毛细血管乳酸浓度≥8.0mmol/L,(3)在 6-20 Borg 量表上,运动停止时的感觉用力程度>17。
在 51 例患者中,分别有 2 例、6 例和 35 例患者符合第一、第二和第三个标准。未发现完成标准与患者特征(如性别、年龄)之间存在相关关系。
尽管本研究结果表明应用的 GXT 具有一定的可行性,但大多数参与者并未达到 ACSM 标准。因此,这项研究对 GXT 方案和 ACSM 标准是否适用于这组患者提出了质疑。